E
Eva Martinez-Balibrea
Researcher at Autonomous University of Barcelona
Publications - 46
Citations - 1981
Eva Martinez-Balibrea is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 21, co-authored 43 publications receiving 1638 citations. Previous affiliations of Eva Martinez-Balibrea include Wellcome Trust Centre for Human Genetics & Laboratory of Molecular Biology.
Papers
More filters
Journal ArticleDOI
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Eva Martinez-Balibrea,Anna Martínez-Cardús,Alba Ginés,Vicenç Ruiz de Porras,Catia Moutinho,Laura Layos,Jose Luis Manzano,Cristina Buges,Sara Bystrup,Manel Esteller,Manel Esteller,Albert Abad +11 more
TL;DR: This review will be focused on recent discoveries about oxaliplatin tumor-related resistance mechanisms, including alterations in transport, detoxification, DNA damage response and repair, cell death (apoptotic and nonapoptosis), and epigenetic mechanisms.
Journal ArticleDOI
Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
Dan Rosmarin,Claire Palles,David N. Church,Enric Domingo,Angela M. Jones,Elaine C. Johnstone,Haitao Wang,Sharon Love,Patrick Julier,Claire Scudder,George Nicholson,Anna González-Neira,Miguel Martin,Daniel Sargent,Erin Green,Howard McLeod,Ulrich M. Zanger,Matthias Schwab,Michael S. Braun,Matthew T. Seymour,L.C. Thompson,Benjamin Lacas,Valérie Boige,Nuria Ribelles,Shoaib Afzal,Henrik Enghusen,Søren Astrup Jensen,M. Etienne-Grimaldi,Gérard Milano,Mia Wadelius,Bengt Glimelius,Hans Garmo,Milena Gusella,Thierry Lecomte,Pierre Laurent-Puig,Eva Martinez-Balibrea,Rohini Sharma,Jesus Garcia-Foncillas,Zdenek Kleibl,Alain Morel,Jean Pierre Pignon,Rachel Midgley,David J. Kerr,Ian Tomlinson +43 more
TL;DR: A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently comprise only the four DPYD and TYMS variants above, but the test panel might be extended to include additional, rare DPYD variants functionally equivalent to *2A and 2846A, though insufficient evidence supports its use in bolus, infusional, or combination FU.
Journal ArticleDOI
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano,Laura Layos,Cristina Buges,Maria de los Llanos Gil,Laia Vilà,Eva Martinez-Balibrea,Anna Martínez-Cardús +6 more
TL;DR: Mechanisms of resistance to targeted therapy and strategies to overcome them are commented on.
Journal ArticleDOI
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Ming Yin,Jingrong Yan,Eva Martinez-Balibrea,Francesco Graziano,Heinz-Josef Lenz,Hyo-Jin Kim,Jacques Robert,Seock-Ah Im,Wei Shu Wang,M. Etienne-Grimaldi,Qingyi Wei +10 more
TL;DR: NER ERCC1 rs11615C>T and ERCC2 rs13181T>G polymorphisms are useful prognostic factors in oxaliplatin-based treatment of gastric and colorectal cancer and are found to be consistent and clinically substantial risk or hazard for TR, PFS, and OS in the oxali platin-treated cancer patients with an ethnic discrepancy.
Journal ArticleDOI
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
Vicenç Ruiz de Porras,Sara Bystrup,Anna Martínez-Cardús,Raquel Pluvinet,Lauro Sumoy,Lynne M. Howells,Mark I. James,Chinenye Iwuji,Jose Luis Manzano,Laura Layos,Cristina Buges,Albert Abad,Eva Martinez-Balibrea +12 more
TL;DR: It is suggested that combination of OXA + Curcumin could be an effective treatment, for which CXCL1 could be used as a predictive marker, in CRC patients.